{"id":493092,"date":"2021-05-13T09:03:27","date_gmt":"2021-05-13T13:03:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/"},"modified":"2021-05-13T09:03:27","modified_gmt":"2021-05-13T13:03:27","slug":"parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/","title":{"rendered":"Parexel Recognized as Most Favored Provider in\u00a0ISR CRO Phase I Quality Benchmarking Report"},"content":{"rendered":"<h2>\nRecognition marks fourth consecutive year as top-ranked Phase I\u00a0provider to work with; Company ranked among top-two global CROs for\u00a0Service Provider Leadership, Familiarity, Use and Preference in Phase I<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">BOSTON and DURHAM, N.C., May  13, 2021  (GLOBE NEWSWIRE) &#8212; Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance world health, today announced it ranked as the Most Favored Provider for Phase I services in a new report released May 10 by Industry Standard Research (ISR). Parexel was one of two CROs to garner the highest scores across Service Provider Leadership, Familiarity, Use and Preference in Phase I services.<\/p>\n<p>ISR\u2019s report, titled \u201cPhase I CRO Benchmarking (13<sup>th<\/sup> Edition)\u201d surveyed 191 biopharmaceutical professionals and 500 service provider encounters across North America, Europe and Asia, evaluating 40 CROs on 22 attributes across five categories (Budget Factors, Delivery Factors, Staff Characteristics, Accessibility and Services).<\/p>\n<p>\u201cThis recognition is a testament to our colleagues around the world and the passion and expertise they bring to their work every day,\u201d said Jamie Macdonald, CEO. \u201cThis past year has challenged all of us in the industry to bring our best to the drug development process and to find new and innovative ways to help patients. Our performance in the ISR survey underscores our deep commitment to putting patients at the heart of everything we do.\u201d<\/p>\n<p>\n        <strong>About Parexel<\/strong><br \/>\n        <br \/>Parexel supports the development of innovative new medicines to improve the health of patients. We provide services to help life sciences and biopharmaceutical clients everywhere transform scientific discoveries into new treatments. From\u00a0decentralized\u00a0clinical trials to regulatory consulting services to\u00a0leveraging real world insights, our therapeutic, technical, and functional ability is underpinned by a deep conviction in what we do.\u00a0Parexel was named \u201cBest Contract Research Organization\u201d in\u00a0December 2020\u00a0by an independent panel for\u00a0<em>Informa Pharma Intelligence<\/em>.\u00a0For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IXANdtjNrisJr0HL1uHHlUF5lV_79w4KqTShXho1g00fqnhBJ8IM7bwBCDoSkffgw1tcYxV4NEwVk8HHz6Ke0Q==\" rel=\"nofollow noopener\" target=\"_blank\"><u>parexel.com<\/u><\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6A9bjLP3wXH-gt8o4D4563CS33fU2HRF4rjBt1H-rFabqK2Pacy5KQ8X6IaGTQ0invlq2gjHO1PunTRqc9K256v1dfNPmy42kLCthGtkXD0=\" rel=\"nofollow noopener\" target=\"_blank\"><u>LinkedIn<\/u><\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ap6LxB-kyT1hnRHJzrJWyxekh4PF5ciD-Kftk9ErQcQtVwWGe02W5EmsYC53ZM2pZ5v5MRIC4mu42etzR39b2A==\" rel=\"nofollow noopener\" target=\"_blank\"><u>Twitter<\/u><\/a><u>,<\/u>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d_o5VtDMzgc-IyPEkgSo6JGO6bX6lxclB5Px0itx8JCRkn0Cz_P9j8RR8TlyxSGp5ftzXDd68qvg7FRJLxArgtsRqrs2CRBI6gR7YcU1Guc=\" rel=\"nofollow noopener\" target=\"_blank\"><u>Instagram<\/u><\/a>.<\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Christine Rogers<br \/>Vice President, Corporate Communications<br \/>984-900-6485<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nHtsiH8CcWeO7Ksou-BNmJxgMHUEfvyGj0oymXQdA1MV-m9B_z1ViNpnDP6xlnuIcdNflCvDju_cQwS37B4zdcfMxfxQdRymKUCaqY11pHtj2ZYUwD_1wfrRBcIrQnER\" rel=\"nofollow noopener\" target=\"_blank\">Christine.rogers@parexel.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTU5NiM0MTgxNzIzIzIwMDg1OTY=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/d53b6b22-5c23-4878-98f7-6448a628b902\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Recognition marks fourth consecutive year as top-ranked Phase I\u00a0provider to work with; Company ranked among top-two global CROs for\u00a0Service Provider Leadership, Familiarity, Use and Preference in Phase I BOSTON and DURHAM, N.C., May 13, 2021 (GLOBE NEWSWIRE) &#8212; Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance world health, today announced it ranked as the Most Favored Provider for Phase I services in a new report released May 10 by Industry Standard Research (ISR). Parexel was one of two CROs to garner the highest scores across Service Provider Leadership, Familiarity, Use and Preference in Phase I services. ISR\u2019s report, titled \u201cPhase I CRO Benchmarking (13th Edition)\u201d surveyed 191 biopharmaceutical professionals &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Parexel Recognized as Most Favored Provider in\u00a0ISR CRO Phase I Quality Benchmarking Report&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-493092","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Parexel Recognized as Most Favored Provider in\u00a0ISR CRO Phase I Quality Benchmarking Report - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Parexel Recognized as Most Favored Provider in\u00a0ISR CRO Phase I Quality Benchmarking Report - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Recognition marks fourth consecutive year as top-ranked Phase I\u00a0provider to work with; Company ranked among top-two global CROs for\u00a0Service Provider Leadership, Familiarity, Use and Preference in Phase I BOSTON and DURHAM, N.C., May 13, 2021 (GLOBE NEWSWIRE) &#8212; Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance world health, today announced it ranked as the Most Favored Provider for Phase I services in a new report released May 10 by Industry Standard Research (ISR). Parexel was one of two CROs to garner the highest scores across Service Provider Leadership, Familiarity, Use and Preference in Phase I services. ISR\u2019s report, titled \u201cPhase I CRO Benchmarking (13th Edition)\u201d surveyed 191 biopharmaceutical professionals &hellip; Continue reading &quot;Parexel Recognized as Most Favored Provider in\u00a0ISR CRO Phase I Quality Benchmarking Report&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-13T13:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTU5NiM0MTgxNzIzIzIwMDg1OTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Parexel Recognized as Most Favored Provider in\u00a0ISR CRO Phase I Quality Benchmarking Report\",\"datePublished\":\"2021-05-13T13:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\\\/\"},\"wordCount\":343,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNTU5NiM0MTgxNzIzIzIwMDg1OTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\\\/\",\"name\":\"Parexel Recognized as Most Favored Provider in\u00a0ISR CRO Phase I Quality Benchmarking Report - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNTU5NiM0MTgxNzIzIzIwMDg1OTY=\",\"datePublished\":\"2021-05-13T13:03:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNTU5NiM0MTgxNzIzIzIwMDg1OTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNTU5NiM0MTgxNzIzIzIwMDg1OTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Parexel Recognized as Most Favored Provider in\u00a0ISR CRO Phase I Quality Benchmarking Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Parexel Recognized as Most Favored Provider in\u00a0ISR CRO Phase I Quality Benchmarking Report - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/","og_locale":"en_US","og_type":"article","og_title":"Parexel Recognized as Most Favored Provider in\u00a0ISR CRO Phase I Quality Benchmarking Report - Market Newsdesk","og_description":"Recognition marks fourth consecutive year as top-ranked Phase I\u00a0provider to work with; Company ranked among top-two global CROs for\u00a0Service Provider Leadership, Familiarity, Use and Preference in Phase I BOSTON and DURHAM, N.C., May 13, 2021 (GLOBE NEWSWIRE) &#8212; Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance world health, today announced it ranked as the Most Favored Provider for Phase I services in a new report released May 10 by Industry Standard Research (ISR). Parexel was one of two CROs to garner the highest scores across Service Provider Leadership, Familiarity, Use and Preference in Phase I services. ISR\u2019s report, titled \u201cPhase I CRO Benchmarking (13th Edition)\u201d surveyed 191 biopharmaceutical professionals &hellip; Continue reading \"Parexel Recognized as Most Favored Provider in\u00a0ISR CRO Phase I Quality Benchmarking Report\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-13T13:03:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTU5NiM0MTgxNzIzIzIwMDg1OTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Parexel Recognized as Most Favored Provider in\u00a0ISR CRO Phase I Quality Benchmarking Report","datePublished":"2021-05-13T13:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/"},"wordCount":343,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTU5NiM0MTgxNzIzIzIwMDg1OTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/","name":"Parexel Recognized as Most Favored Provider in\u00a0ISR CRO Phase I Quality Benchmarking Report - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTU5NiM0MTgxNzIzIzIwMDg1OTY=","datePublished":"2021-05-13T13:03:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTU5NiM0MTgxNzIzIzIwMDg1OTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTU5NiM0MTgxNzIzIzIwMDg1OTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-recognized-as-most-favored-provider-in-isr-cro-phase-i-quality-benchmarking-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Parexel Recognized as Most Favored Provider in\u00a0ISR CRO Phase I Quality Benchmarking Report"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/493092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=493092"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/493092\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=493092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=493092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=493092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}